Literature DB >> 15880822

Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus.

Stephan Meller1, Franziska Winterberg, Michel Gilliet, Anja Müller, Ingrida Lauceviciute, Juliane Rieker, Norbert J Neumann, Robert Kubitza, Michael Gombert, Erich Bünemann, Ulrike Wiesner, Petra Franken-Kunkel, Holger Kanzler, Marie-Caroline Dieu-Nosjean, Ali Amara, Thomas Ruzicka, Percy Lehmann, Albert Zlotnik, Bernhard Homey.   

Abstract

OBJECTIVE: To investigate the activation and recruitment pathways of relevant leukocyte subsets during the initiation and amplification of cutaneous lupus erythematosus (LE).
METHODS: Quantitative real-time polymerase chain reaction was used to perform a comprehensive analysis of all known chemokines and their receptors in cutaneous LE lesions, and the cellular origin of these chemokines and receptors was determined using immunohistochemistry. Furthermore, cytokine- and ultraviolet (UV) light-mediated activation pathways of relevant chemokines were investigated in vitro and in vivo.
RESULTS: In the present study, we identified the CXCR3 ligands CXCL9 (interferon-gamma [IFNgamma]-induced monokine), CXCL10 (IFNgamma-inducible protein 10), and CXCL11 (IFN-inducible T cell alpha chemoattractant) as being the most abundantly expressed chemokine family members in cutaneous LE. Expression of these ligands corresponded with the presence of a marked inflammatory infiltrate consisting of mainly CXCR3-expressing cells, including skin-homing lymphocytes and blood dendritic cell antigen 2-positive plasmacytoid dendritic cells (PDCs). Within cutaneous LE lesions, PDCs accumulated within the dermis and were activated to produce type I IFN, as detected by the expression of the IFNalpha-inducible genes IRF7 and MxA. IFNalpha, in turn, was a potent and rapid inducer of CXCR3 ligands in cellular constituents of the skin. Furthermore, we demonstrated that the inflammatory CXCR3 ligands cooperate with the homeostatic chemokine CXCL12 (stromal cell-derived factor 1) during the recruitment of pathogenically relevant leukocyte subsets. Moreover, we showed that UVB irradiation induces the release of CCL27 (cutaneous T cell-attracting chemokine) from epidermal compartments into dermal compartments and up-regulates the expression of a distinct set of chemokines in keratinocytes.
CONCLUSION: Taken together, our data suggest an amplification cycle in which UV light-induced injury induces apoptosis, necrosis, and chemokine production. These mechanisms, in turn, mediate the recruitment and activation of autoimmune T cells and IFNalpha-producing PDCs, which subsequently release more effector cytokines, thus amplifying chemokine production and leukocyte recruitment, finally leading to the development of a cutaneous LE phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880822     DOI: 10.1002/art.21034

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  59 in total

Review 1.  Rosacea: The cytokine and chemokine network.

Authors:  Peter Arne Gerber; Bettina Alexandra Buhren; Martin Steinhoff; Bernhard Homey
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

2.  CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues.

Authors:  Vanja Sisirak; Nelly Vey; Béatrice Vanbervliet; Thomas Duhen; Isabelle Puisieux; Bernhard Homey; Edward P Bowman; Giorgio Trinchieri; Bertrand Dubois; Dominique Kaiserlian; Sergio A Lira; Alain Puisieux; Jean-Yves Blay; Christophe Caux; Nathalie Bendriss-Vermare
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

Review 3.  Plasma cells as an innovative target in autoimmune disease with renal manifestations.

Authors:  Falk Hiepe; Andreas Radbruch
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

Review 4.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 5.  Dendritic cells in systemic lupus erythematosus.

Authors:  Heather M Seitz; Glenn K Matsushima
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

6.  The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score.

Authors:  I Braunstein; R Klein; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2012-05       Impact factor: 9.302

7.  Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.

Authors:  K Masek-Hammerman; E Peeva; A Ahmad; S Menon; M Afsharvand; R Peng Qu; J B Cheng; J Syed; Y Zhan; S P O'Neil; S Pleasic-Williams; L A Cox; D Beidler
Journal:  Clin Exp Immunol       Date:  2015-11-09       Impact factor: 4.330

8.  Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus.

Authors:  K O Kong; A W Tan; B Y H Thong; T Y Lian; Y K Cheng; C L Teh; E T Koh; H H Chng; W G Law; T C Lau; K P Leong; B P Leung; H S Howe
Journal:  Clin Exp Immunol       Date:  2009-01-23       Impact factor: 4.330

9.  Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1.

Authors:  Jianhua Liu; Celine C Berthier; J Michelle Kahlenberg
Journal:  Arthritis Rheumatol       Date:  2017-08-08       Impact factor: 10.995

10.  A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE.

Authors:  Matilda W Nicholas; Mary Anne Dooley; Susan L Hogan; Jennifer Anolik; John Looney; Ingnacio Sanz; Stephen H Clarke
Journal:  Clin Immunol       Date:  2008-02       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.